| Primary |
| Colorectal Cancer Metastatic |
16.9% |
| Colon Cancer |
15.4% |
| Colorectal Cancer |
8.9% |
| Colon Cancer Metastatic |
6.6% |
| Glioblastoma Multiforme |
6.4% |
| Rectal Cancer |
6.2% |
| Metastatic Colorectal Cancer |
5.8% |
| Pancreatic Carcinoma |
5.5% |
| Gastrointestinal Carcinoma |
4.5% |
| Product Used For Unknown Indication |
4.3% |
| Chemotherapy |
3.6% |
| Neuroblastoma |
2.3% |
| Pancreatic Carcinoma Metastatic |
2.3% |
| Breast Cancer Metastatic |
2.1% |
| Adenocarcinoma |
1.9% |
| Adenocarcinoma Of Colon |
1.7% |
| Rectal Cancer Stage Iv |
1.7% |
| Lung Adenocarcinoma Stage Iii |
1.5% |
| Gastric Cancer |
1.3% |
| Prophylaxis Of Nausea And Vomiting |
1.1% |
|
| Vomiting |
12.8% |
| Neuropathy Peripheral |
9.6% |
| Diarrhoea |
6.4% |
| Febrile Neutropenia |
5.3% |
| Pulmonary Embolism |
5.3% |
| Thrombocytopenia |
5.3% |
| Toxicity To Various Agents |
5.3% |
| Abdominal Pain |
4.3% |
| Acute Myeloid Leukaemia |
4.3% |
| Muscular Weakness |
4.3% |
| Neutropenia |
4.3% |
| Paraesthesia |
4.3% |
| Respiratory Failure |
4.3% |
| Speech Disorder |
4.3% |
| Tachycardia |
4.3% |
| Chronic Myeloid Leukaemia |
3.2% |
| Erythema |
3.2% |
| Hypokalaemia |
3.2% |
| Pulmonary Fibrosis |
3.2% |
| Pyrexia |
3.2% |
|
| Secondary |
| Colorectal Cancer |
27.9% |
| Colorectal Cancer Metastatic |
14.8% |
| Colon Cancer |
7.9% |
| Colon Cancer Metastatic |
7.2% |
| Drug Use For Unknown Indication |
6.5% |
| Product Used For Unknown Indication |
4.8% |
| Prophylaxis |
4.3% |
| Rectal Cancer Metastatic |
3.7% |
| Rectal Cancer |
3.1% |
| Pancreatic Carcinoma |
3.0% |
| Large Intestine Carcinoma |
2.4% |
| Glioblastoma Multiforme |
2.4% |
| Glioblastoma |
2.2% |
| Rectal Cancer Recurrent |
1.8% |
| Gastric Cancer |
1.7% |
| Hypertension |
1.6% |
| Prophylaxis Of Nausea And Vomiting |
1.4% |
| Metastatic Colorectal Cancer |
1.1% |
| Neoplasm |
1.1% |
| Colon Cancer Recurrent |
1.0% |
|
| Vomiting |
12.3% |
| Interstitial Lung Disease |
9.5% |
| Stomatitis |
9.0% |
| Neutropenia |
7.4% |
| White Blood Cell Count Decreased |
6.9% |
| Diarrhoea |
5.6% |
| Pyrexia |
5.6% |
| Thrombocytopenia |
4.6% |
| Pulmonary Embolism |
4.4% |
| Febrile Neutropenia |
4.1% |
| Paronychia |
3.8% |
| Sepsis |
3.6% |
| General Physical Health Deterioration |
3.1% |
| Intestinal Obstruction |
3.1% |
| Malaise |
3.1% |
| Urinary Tract Infection |
3.1% |
| Weight Decreased |
3.1% |
| Blood Creatinine Increased |
2.8% |
| Disease Progression |
2.6% |
| Dermatitis Acneiform |
2.3% |
|
| Concomitant |
| Colorectal Cancer |
26.1% |
| Colon Cancer Metastatic |
12.2% |
| Colon Cancer |
9.7% |
| Rectal Cancer Metastatic |
8.8% |
| Drug Use For Unknown Indication |
8.1% |
| Prophylaxis |
7.8% |
| Rectal Cancer |
5.3% |
| Colorectal Cancer Metastatic |
4.4% |
| Colon Cancer Recurrent |
2.6% |
| Rectal Cancer Recurrent |
2.4% |
| Prophylaxis Of Nausea And Vomiting |
1.9% |
| Large Intestine Carcinoma |
1.6% |
| Chemotherapy |
1.4% |
| Pancreatic Neuroendocrine Tumour |
1.4% |
| Hypertension |
1.3% |
| Product Used For Unknown Indication |
1.3% |
| Glioblastoma Multiforme |
1.2% |
| Premedication |
1.2% |
| Testicular Neoplasm |
0.8% |
| Diabetes Mellitus |
0.6% |
|
| Dermatitis Acneiform |
10.6% |
| Interstitial Lung Disease |
9.7% |
| Vomiting |
8.4% |
| Stomatitis |
7.0% |
| Hypomagnesaemia |
6.2% |
| Pulmonary Embolism |
5.3% |
| Pyrexia |
4.8% |
| Rash |
4.8% |
| Diarrhoea |
4.4% |
| Disease Progression |
4.4% |
| Death |
4.0% |
| Peritonitis |
4.0% |
| Renal Failure Acute |
4.0% |
| White Blood Cell Count Decreased |
4.0% |
| Colorectal Cancer |
3.5% |
| Neuropathy Peripheral |
3.5% |
| Paronychia |
3.1% |
| Weight Decreased |
3.1% |
| Necrotising Fasciitis |
2.6% |
| Pneumonia |
2.6% |
|
| Interacting |
| Epilepsy |
40.0% |
| Antifungal Prophylaxis |
20.0% |
| Chemotherapy |
20.0% |
| Uterine Cancer |
20.0% |
|
| Hepatic Function Abnormal |
50.0% |
| Uterine Cancer |
50.0% |
|
